Login to Your Account

Millendo raises $62M to advance in-licensed Astrazeneca endocrine disease therapy

By Michael Fitzhugh
Staff Writer

Tuesday, January 5, 2016

Millendo Therapeutics Inc., financed with a new $62 million series B investment led by New Enterprise Associates (NEA), has exclusively licensed rights to develop and commercialize MLE4901, a phase II neurokinin 3 receptor antagonist licensed from Astrazeneca plc for the treatment of PCOS.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription